Better Health for All

Jasper Therapeutics' core product, briquilimab, is in clinical development for serious diseases like chronic urticaria, sickle cell disease, and beta thalassemia.

Clinical trials show high efficacy, with 81-100% complete or clinical response rates in various cohorts for chronic urticaria, and 100% donor myeloid chimerism in 2 of 3 sickle cell patients. However, a drug product lot issue led to the halting of asthma and SCID development programs and affected 10-13 patients in CSU trials, resulting in lower than expected efficacy. The company reported no serious adverse events (SAEs) and no grade 3 or higher adverse events (AEs) in the 180mg cohort of the SPOTLIGHT study and the BEACON study. However, 50% of participants in the 180mg cohort experienced grade 1 or 2 neutrophil count decreases, and a drug product lot issue affected 10 of 13 patients in multi-dose cohorts, leading to the halting of an asthma study and SCID development. The company disclosed the drug product lot issue and its impact on trials, including lower than expected tryptase levels and no discernible impact on UAS7 scores in affected patients. They are investigating the issue and plan to enroll additional patients. The company states a commitment to conducting R&D ethically and protecting personal data, with policies against unauthorized access or disclosure of patient information. However, specific details on data protection measures or ethical frameworks beyond general statements are not provided. Jasper Therapeutics is halving its workforce, impacting approximately 65 employees, and anticipates $1.8 million to $2.2 million in reorganization expenditures. The company states a commitment to building a diverse, equitable, and inclusive workplace and is an equal opportunity employer, but no specific health equity programs are detailed. The company also states a policy to conduct business in an environmentally responsible way that minimizes environmental impacts, but no specific health externalities are mentioned. The company holds periodic training sessions for employees on compliance, but no public health education initiatives are detailed.

Fair Money & Economic Opportunity

Jasper Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapies, not a financial institution.

The company does not offer lending, deposit, or other consumer financial services. Therefore, all KPIs related to fair money and economic opportunity, such as underserved client share, pricing fairness, exploitative fee exposure, inclusion initiatives, data accessibility for financial data, fair lending compliance, wealth building outcomes, profit reinvestment in community finance, financial literacy initiatives, debt burden ratio, geographic inclusion for banking services, and product simplicity for financial products, are not applicable to its core business model. While the company faces a securities class action lawsuit regarding investor relations and product manufacturing, this does not relate to fair lending or consumer financial services.

Honest & Fair Business

The company maintains a confidential and anonymous financial concern hotline, as required by the SEC, for reporting accounting, internal controls, or auditing matters.

This hotline allows for secure web form or phone submission and provides a confirmation code for message status tracking, indicating that reports are acknowledged and tracked.

No War, No Weapons

Jasper Therapeutics, Inc. is a biotechnology company focused on developing therapies for medical conditions, such as hematopoietic stem cell transplantation and mast cell-driven diseases.

Its corporate profile and other provided articles contain no information indicating any involvement in defense or arms-related activities. Therefore, its core business is assessed as having no defense or arms-related activities.

Planet-Friendly Business

The provided articles contain no specific, quantifiable data points or verifiable actions related to any of the 'Planet-Friendly Business' KPIs. While one article mentions the company's policy to conduct business in an environmentally responsible way, minimize environmental impacts, and reduce waste,

these are stated commitments and expectations rather than evidenced outcomes or metrics. There is no information on emissions, renewable energy use, water consumption, green building certifications, waste diversion rates, climate targets, or any other specific environmental performance indicators.

Zero Waste & Sustainable Products

No specific, concrete data points were found in the provided articles for Jasper Therapeutics, Inc. (JSPR.US) regarding any of the 'Zero Waste & Sustainable Products' KPIs. The articles either did not mention JSPR.US in relation to these metrics

, discussed the broader industry without company-specific data , or pertained to a different company (JSR Group).